first
record
outbreak
ebola
hemorrhag
fever
ehf
occur
octob
demo
cratic
republ
congo
outbreak
thought
share
mani
featur
break
caus
zair
ebola
viru
start
rural
forest
area
hunt
bush
meat
common
patient
admit
region
hospit
grave
condit
symptom
resembl
malaria
typhoid
fever
lassa
fever
yellow
fever
influenza
epidem
sever
challeng
health
care
system
west
african
countri
total
ill
prepared
commun
caus
panic
social
upheav
requir
militari
unit
bring
affect
territori
control
yet
import
lesson
learn
current
situat
ehf
health
care
system
prepar
outbreak
virtual
countri
vaccin
difficult
develop
highli
effect
broad
spectrum
antivir
chemo
therapi
agent
unavail
outbreak
viru
zair
ebolaviru
causal
agent
ehf
outbreak
west
africa
ebola
viru
first
identifi
caus
sporad
ehf
outbreak
high
mortal
africa
assign
cons
quentli
group
pathogen
potenti
bio
terror
agent
term
gener
virolog
ebola
viru
current
refer
standard
pathogen
studi
basic
import
solv
complex
problem
treat
prevent
viru
infect
speci
zair
ebolaviru
pathogen
speci
genu
ebolaviru
famili
filovirida
order
mononegaviral
famili
filovirida
infect
reston
ebolaviru
asymptomat
four
speci
highli
pathogen
human
taxonomi
genu
ebolaviru
consid
special
articl
publish
virus
team
includ
russian
research
contribut
substanti
studi
problem
russia
abroad
current
classif
genu
ebolaviru
shown
fig
ebola
viru
found
primat
field
mice
bat
bat
infect
lead
diseas
outbreak
virtual
asymptomat
fact
sug
gest
bat
particular
fruit
bat
famili
pteropodida
natur
reservoir
intermedi
host
ebola
viru
genet
analysi
ebola
viru
isol
show
current
outbreak
start
viru
transmiss
straw
color
fruit
bat
eidolon
helvum
human
note
greater
rang
intermedi
host
possibl
viru
interest
virus
famili
filovirida
belong
limit
group
virus
known
non
retrovir
integr
rna
virus
nirv
whose
specif
element
identifi
anim
genom
high
structur
similar
observ
receptor
protein
gp
ebola
viru
env
protein
endogen
retrovirus
placent
syn
cytin
human
common
element
ebola
viru
retroviru
princip
import
understand
key
factor
ebola
viru
pathogen
high
similar
addit
alli
detect
ebola
viru
gp
well
known
influenza
viru
hemagglutinin
facilit
better
understand
gp
tertiari
structur
inhibi
tor
design
team
epidemiologist
identifi
ebola
viru
causal
agent
hemorrhag
fever
outbreak
occur
ebola
river
valley
zair
central
africa
total
ehf
outbreak
regist
sinc
time
outbreak
start
guinea
west
africa
spread
liberia
sierra
leon
nigeria
phylo
genet
analysi
ebola
viru
genom
sequenc
give
ground
think
viru
strain
respons
outbreak
rel
recent
found
way
central
west
africa
phylogenet
analysi
confirm
genet
similar
iti
ebola
viru
lineag
involv
three
last
ehf
outbreak
find
suggest
common
ancestor
virus
involv
support
hypothesi
ehf
outbreak
caus
independ
transmiss
viru
one
genet
ical
divers
popul
genet
similar
close
phylogenet
relationship
genom
ebola
virus
indic
singl
act
tran
mission
natur
reservoir
follow
stabl
transmiss
infect
among
human
lead
epidem
outbreak
epidemiolog
situat
basic
differ
instanc
epidem
avian
flu
character
multipl
focal
break
endem
region
low
transmiss
rate
among
human
henc
ebola
viru
infect
seem
extrem
contagi
estim
singl
event
cross
speci
barrier
would
enough
viru
spread
rapidli
popula
tion
ehf
outbreak
start
decemb
involv
mostli
guinea
liberia
seneg
sierra
leon
nigeria
among
african
countri
case
observ
unit
state
european
countri
occur
healthcar
worker
mission
ari
estim
publish
mass
media
risk
ehf
transfer
countri
includ
russia
base
passeng
traffic
statist
epidemiolog
situat
late
octob
forecast
subsequ
period
earli
shown
fig
predict
num
ber
case
death
ebola
chang
rapidli
number
death
may
reach
one
million
peopl
nearest
futur
accord
estim
mod
erat
forecast
estim
number
case
pri
mari
foci
ehr
outbreak
sever
ten
thou
sand
peopl
octob
ebola
morbid
rate
ceas
grow
nigeria
earli
sign
spread
infect
control
use
anti
epidem
measur
ebola
viru
rna
viru
ie
repro
duction
depend
polymeras
complex
ebola
viru
genom
singl
strand
rna
approxim
nt
seven
open
read
frame
identifi
genom
code
major
viru
protein
occur
follow
order
np
gpsgp
l
fig
gene
separ
short
untransl
sequenc
leader
trailer
region
transcrib
harbor
control
signal
transcript
replica
tion
genom
rna
packag
viru
particl
function
viru
protein
summar
tabl
ebola
viru
gene
code
one
protein
except
gp
produc
main
translat
product
gp
also
sgp
result
transcript
rna
edit
first
amino
acid
residu
sgp
n
termin
region
gp
c
termin
sequenc
sgp
uniqu
infect
cell
secret
sgp
homodim
stabil
disulfid
bond
sgp
import
compon
system
help
ebola
viru
evad
immun
respons
content
peripher
blood
increas
cours
infect
shorten
sgp
ssgp
identifi
recent
among
ebola
viru
protein
gp
studi
comprehens
fig
spatial
struc
ture
known
gp
attract
particular
interest
execut
import
function
viru
life
cycl
interact
cell
receptor
ensur
viru
fusion
membran
cell
infect
start
gp
bind
tim
cell
protein
belong
class
receptor
po
sess
cell
immunoglobulin
like
mucin
like
domain
tim
famili
protein
play
key
role
regul
cell
immun
respons
viru
infect
tim
receptor
involv
allerg
respons
pathogenesi
asthma
ebola
viru
enter
cell
via
clathrin
mediat
endoci
tosi
receptor
mediat
macropinocytosi
interact
niemannpick
cholesterol
transport
also
found
play
role
viru
entri
cell
late
endosom
stage
acidosi
highli
glycosyl
mucin
like
domain
nonprocess
gp
cleav
endosom
cellular
furin
cystein
proteas
catl
catb
proteolysi
occur
sgp
format
well
gp
proteolyt
process
lead
conform
chang
trimer
initi
fusion
endosom
viru
membran
releas
viru
nucleocapsid
cytoplasm
note
gp
con
tain
viru
neutral
antibodi
determin
consequ
often
use
design
anti
ehf
vac
cine
protect
host
immun
system
involv
sever
ebola
viru
protein
tabl
particular
suppress
innat
immun
inhibit
interferon
product
prevent
transport
phosphoryl
nucleu
thu
suppress
interferon
mediat
antiviru
respons
mani
molecular
target
ebola
viru
among
compon
host
immun
system
list
extend
level
bodi
protect
viru
infect
gener
ebola
viru
act
potent
immu
nosuppress
agent
caus
immunoparalysi
render
organ
incap
recogn
viru
antigen
rapid
develop
infect
multilevel
immunosuppress
system
prevent
bodi
produc
adequ
immun
respons
circumst
great
extent
respons
numer
death
ehf
occur
earli
day
diseas
sever
condit
includ
system
organ
failur
hem
orrhag
pulmonari
edema
sepsi
dissemin
intravascular
coagul
dic
hemorrhag
fever
ehf
develop
includ
follow
stage
incub
period
earli
symptomat
stage
late
symptomat
stage
termin
recov
eri
period
anoth
classif
broad
use
base
consequ
develop
sign
symptom
vital
organ
involv
tabl
total
main
clinic
sign
symptom
ehf
resembl
sepsi
clinic
statu
ehf
patient
character
system
viru
repli
cation
high
level
viremia
cytokin
storm
gener
immun
suppress
resembl
immunoparalysi
septic
condit
impair
function
intesti
nal
vascular
epithelia
impair
coagul
ti
sue
edema
increas
total
vascular
permeabl
patient
die
multipl
organ
failur
acut
respiratori
distress
coagulopathi
develop
ment
infect
process
caus
ebola
viru
main
compon
pathogenesi
shown
fig
ebola
viru
infect
immun
cell
import
consequ
infect
leuko
penia
dissemin
viru
infect
bodi
suppress
present
viru
antigen
antigen
present
cell
dysfunct
apoptosi
dendrit
cell
infect
endotheli
cell
alter
bar
rier
function
vascular
endothelium
lead
hypovolem
shock
hemorrhag
tissu
edema
activ
tissu
factor
plasminogen
lead
fatal
coagulopathi
immun
respons
sup
press
mani
level
relat
primarili
effect
immunosuppress
domain
gp
cytokin
storm
overproduct
pro
inflam
matori
cytokin
caus
system
inflamma
tion
syndrom
diffus
inflammatori
reaction
tissu
blood
vessel
ehf
sequel
develop
presenc
cytokin
storm
immunoparalisi
due
infect
macrophag
dendrit
cell
soon
discoveri
viru
protein
act
interferon
antagonist
result
identifi
protein
block
interferon
pro
duction
earli
infect
gener
thought
play
crucial
role
pathogenesi
ehf
contribut
suppress
antiviru
cell
defens
oxid
stress
endotheli
cell
infect
induc
synthesi
enzym
caus
oxid
stress
mass
apoptosi
utmost
import
pathogenesi
ebola
viru
infect
infect
endotheli
cell
alter
intercellular
contact
associ
intima
vascular
basement
membran
vessel
synthas
expr
sion
simultan
induc
endotheli
cell
result
overproduct
nitros
stress
caus
peroxynitrit
reactiv
oxi
gen
speci
higher
level
peripher
blood
correl
diseas
sever
high
mortal
erythrocyt
hemolysi
tissu
affect
hemorrhag
edema
lead
destruct
gen
erat
reactiv
oxygen
speci
especi
lung
endotheli
dysfunct
mass
endotheliocyt
apoptosi
viru
particl
bud
lipid
raft
endotheli
cell
thought
destabil
vascular
wall
therebi
caus
bleed
hemorrhag
direct
effect
viru
protein
endotheli
barrier
integr
cannon
also
exclud
less
destruct
effect
exert
tumor
necrosi
fac
tor
tnf
lead
compon
cytokin
storm
note
defect
endotheli
barrier
aris
primarili
cell
con
tact
endotheliocyt
structur
impair
henc
therapi
aim
restor
integr
endot
helial
barrier
protect
endothelium
cytokin
storm
compon
destruct
effect
infect
vascular
endothelium
macroph
age
activ
fig
lead
disrupt
intercellu
lar
contact
caus
endotheli
dysfunct
con
sequent
hemorrhag
tissu
edema
blood
clot
accompani
hemorrhagi
activ
tissu
plasminogen
activ
devel
op
inadequ
compensatori
reaction
inevit
stimul
coagul
cascad
fig
dissemin
intravascular
clot
dic
sever
consequ
process
risk
dic
substanti
reduc
use
activ
pro
tein
c
drug
xigri
treatment
recombi
nant
nematod
anticoagul
protein
found
protect
primat
fatal
ebola
viru
infect
larg
scale
gener
immun
complex
circul
also
consid
factor
provok
blood
clot
diseas
outcom
usual
determin
day
either
acut
phase
crisi
resolv
transit
termin
stage
occur
circumst
show
therapi
window
limit
medic
decis
made
within
short
therefor
immens
impor
tanc
detect
turn
period
interact
ebola
viru
immun
cell
illustr
fig
viru
initi
interact
immun
cell
caus
follow
alter
nk
cell
apoptosi
cooper
lympho
cyte
apoptosi
dendrit
cell
infect
macroph
age
activ
oxid
stress
associ
overproduct
reactiv
oxygen
speci
immunosuppress
target
nk
cell
import
effect
infect
gp
interferon
antagonist
identifi
immunosuppress
viru
protein
higher
pathogen
ebola
viru
compar
marburg
viru
due
sgp
synthesi
antigen
subvers
due
secret
sgp
trun
cate
gp
form
lead
antibodi
neutral
circul
therebi
substanti
reduc
immun
respons
infect
thu
ebola
viru
target
variou
element
host
immun
system
monocyt
macrophag
dendrit
cell
multipl
organ
failur
caus
infect
mass
apoptosi
vascular
lung
endotheli
cell
anti
bodi
depend
enhanc
ade
infect
process
anoth
mechan
involv
stimu
late
viru
infect
facilit
host
immu
niti
evas
viru
capabl
ade
consid
construct
vaccin
known
also
ebola
viru
interact
complement
compon
cell
fc
receptor
promot
spread
infect
among
immun
cell
variou
organ
tissu
diagnost
monitor
essenti
new
infect
aris
known
one
recur
rapid
labora
tori
diagnosi
one
main
prerequisit
reli
abl
infect
control
time
identif
infect
individu
quarantin
activ
impor
tant
time
medic
decis
administ
effec
tive
treatment
time
manner
main
test
employ
laboratori
diagnosi
ehf
summa
rize
tabl
rt
pcr
test
central
institut
epidemiolog
russian
feder
servic
surveil
lanc
consum
right
protect
human
well
current
approv
russian
fed
erat
simpl
rapid
test
essenti
diagnosi
primari
foci
infect
rapid
progress
seen
develop
rapid
diagnost
test
basi
biochip
immunochromatograph
strip
variou
modif
elisa
new
approach
propos
sever
russian
project
practic
requir
prioriti
antiviru
drug
limit
agent
effect
ehf
avail
obviou
reason
henc
interven
drug
approv
system
support
vac
cine
antiviru
drug
studi
comprehens
test
primat
gener
opinion
monotherapi
promis
ehf
combin
medic
intens
care
mean
achiev
desir
effect
efficaci
approach
illustr
case
epidemiologist
work
long
time
ehf
focu
sierra
leon
first
sign
diseas
appear
patient
treat
accord
protocol
accept
malaria
ehf
diagnos
pcr
test
transfus
ciprofloxacin
metronidazol
administ
day
ill
patient
airlift
hamburg
admit
intens
care
unit
grave
condit
therapi
aim
primarili
treat
sepsi
patient
recov
ere
discharg
hospit
day
note
patient
receiv
anti
viral
drug
zmapp
cocktail
conclus
made
sever
ehf
case
treat
success
fulli
convent
intens
care
measur
thu
avail
adequ
intens
care
modern
treatment
sepsi
underli
success
therapi
ehf
howev
note
develop
chemotherapeut
modern
pharmacolog
focus
great
extent
commerci
success
excess
profit
evid
fact
design
test
antivir
drug
inhibit
ebolaviru
repli
cation
interest
major
pharmaceuti
cal
compani
worldwid
especi
russia
would
surpris
inde
anaferon
ingavirin
kagotsel
mani
russian
drug
pro
pose
treat
highli
danger
infect
ehf
main
drug
use
prevent
treat
ehf
summar
tabl
vaccin
clear
primari
task
develop
diseas
prevent
vaccin
ensur
safeti
healthcar
worker
perform
larg
scale
vacci
nation
endem
region
west
africa
erad
icat
ehf
attempt
also
made
develop
vac
cine
vaccin
protocol
aim
urgent
di
eas
prevent
contact
person
incub
period
ten
vac
cine
current
develop
evalu
clinic
studi
recombin
technolog
employ
basi
construct
vaccin
ebola
viru
recombin
vaccin
mani
includ
base
vaccinia
viru
venezu
elan
equin
enceph
viru
type
parainfluenza
viru
sever
common
vector
support
vesicular
stomat
viru
chimpanze
adenoviru
base
vaccin
express
ebola
viru
antigen
base
vaccin
consid
promis
anti
adenoviru
immun
widespread
popu
lation
main
drawback
usual
cold
chain
logi
tic
insuffici
vaccin
store
extrem
low
temperatur
liquid
nitro
gen
temperatur
case
storag
prob
lemat
african
countri
render
mass
vaccina
tion
difficult
expens
human
antibodi
zmapp
cocktail
human
monoclon
antibodi
neutral
infec
tion
activ
ebola
viru
blood
tissu
occupi
special
place
among
bio
therapeut
efficaci
verifi
one
patient
logic
list
tabl
took
least
year
basic
research
develop
drug
technolog
implemen
tation
project
worthi
among
best
achiev
centuri
sourc
pride
ministri
health
canada
pathogenesi
base
drug
aim
control
manag
infect
process
prevent
dy
function
vital
organ
sequel
includ
fatal
outcom
drug
actual
target
caus
fatal
outcom
initi
studi
research
vector
state
research
center
virolog
biotechnolog
first
tri
design
drug
would
correct
develop
irrevers
chang
affect
ti
sue
uniqu
drug
desfer
propos
protect
lung
hemorrhag
edema
cons
quent
heme
induc
oxid
stress
anti
antibodi
use
first
time
reduc
damag
effect
cytokin
storm
fibrin
deriv
peptid
domain
fragment
therapeut
use
peptid
known
interact
cadherin
special
interest
peptid
result
plasmin
catalyz
proteolysi
fibrin
therapeut
efficaci
pep
tide
studi
anim
myocardi
rep
erfus
injuri
provid
model
myocardi
infarct
shown
prevent
increas
vascular
permeabl
lipopolysaccharid
induc
septic
shock
model
display
good
therapeut
properti
prevent
increas
vascular
perm
abil
syndrom
model
dengu
viru
induc
shock
studi
mechan
action
show
peptid
prevent
stress
induc
activ
rhoa
kinas
note
high
prolin
content
ghrpldkkreeapslrpa
pppisgggyr
suggest
regulatori
function
toward
pdz
bind
domain
base
preclin
find
use
treat
ehf
patient
sierra
leon
hamburg
therapeut
suc
cess
attribut
directli
use
case
apart
medicin
antivir
drug
base
small
interf
rna
modifi
antisens
oligonucleotid
combin
certain
advan
tage
consider
drawback
recommend
treat
ehf
patient
due
regard
new
data
ehf
pathogenesi
caus
fatal
outcom
develop
institut
influenza
ebola
viru
replic
antivir
therapi
broad
spectrum
chemoth
apeut
prioriti
special
signific
accord
high
level
viremia
accompani
ehf
viral
load
correl
clinic
cours
diseas
etiotrop
therapi
aim
sup
press
viru
replic
utmost
import
ade
nosin
analog
bcx
e
pyrazin
carboxamid
inhibit
viral
rna
depend
rna
polymeras
b
estrogen
receptor
inhibitor
clomiphen
suppress
endosom
stage
infect
c
adenosin
receptor
antagonist
great
interest
attract
small
molecul
low
molecular
weight
compound
test
pre
clinic
phase
clinic
studi
show
efficaci
ehf
set
includ
brincidofovir
favipiravir
umifenovir
bcx
fgi
triazavirin
new
triazolo
purin
triazolo
pyrimidin
deriv
fig
bcx
fgi
triazavirin
consid
promis
tri
azavirin
triazolo
triazin
drug
broad
spec
trum
activ
toward
hemorrhag
fever
virus
although
refer
studi
necessari
test
efficaci
ebola
viru
adenosin
receptor
modul
toll
like
receptor
blocker
found
provid
better
surviv
laboratori
anim
sepsi
accompa
nie
multipl
organ
failur
new
approach
help
substanti
augment
set
drug
effect
ehf
danger
human
diseas
mass
screen
reveal
substanc
unexpect
proper
tie
even
among
approv
drug
drug
actual
requir
ehf
approv
new
indic
new
mechan
action
describ
umifenovir
arbidol
cons
quentli
improv
serv
ebola
viru
rep
licat
inhibitor
studi
institut
influ
enza
made
possibl
complet
design
antivi
ral
agent
seri
expand
activ
spectrum
new
compound
new
inform
develop
drug
vaccin
ebola
viru
avail
mani
web
site
includ
cdc
institut
influenza
